Protocol Ledger

NCT05918107 · Phase II · COMPLETED

A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

Interventional Phase II clinical trial protocol NCT05918107 sponsored by Biotheus in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-13 Enrollment: 31 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05918107
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)31 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05918107
Protocol FieldVerified Registry Value
NCT IdentifierNCT05918107
Consolidated Lead SponsorBiotheus
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment31 participants (ACTUAL)
Registered Start Date2022-08-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI